Regentis Biomaterials Ltd. (NYSE American: RGNT), a regenerative medicine company focused on innovative tissue repair solutions, announced strong interest and engagement from orthopedic surgeons, physicians, and cartilage repair specialists at the 8th International Cartilage Regeneration & Joint Preservation Society (ICRS) Summit, held Oct. 8-10 in Porto, Portugal. The event provided a platform for the company to showcase its lead product, GelrinC, a CE Mark-approved, cell-free hydrogel implant designed to regenerate damaged knee cartilage through a single procedure lasting approximately 10 minutes.
Discussions at the summit centered on GelrinC's potential to address a significant unmet need in orthopedic medicine. In a Phase II study, GelrinC demonstrated approximately 100% greater improvement in overall Knee Injury and Osteoarthritis Outcome Score (KOOS) scores compared with historical microfracture controls at two years. Subsequent MRI analyses showed results consistent with durable, native-like cartilage regeneration, suggesting the treatment could offer a long-lasting solution for patients suffering from cartilage damage.
The strong surgeon interest highlights the medical community's recognition of GelrinC's innovative approach. Regentis is now working to translate this interest into broader clinical adoption through its expanding European Centers of Excellence while advancing its ongoing U.S. Food and Drug Administration pivotal trial. The company's efforts are particularly relevant given that GelrinC aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S., where no off-the-shelf treatment is currently available.
For investors and industry observers, the news underscores Regentis's progress in bringing a potentially disruptive product to market. The positive reception at the ICRS Summit could accelerate partnerships and adoption in Europe, where GelrinC is already approved, and build momentum for U.S. regulatory approval. The company's focus on regenerative medicine aligns with broader trends in healthcare toward less invasive, more effective treatments that can improve patient outcomes and reduce long-term costs.
Regentis Biomaterials Ltd. is dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. Its Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue, including inflamed cartilage and bone. GelrinC, a cell-free, off-the-shelf hydrogel, is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled and synchronous process. For more information, the full press release is available at https://ibn.fm/hcEu4.
The announcement was disseminated through InvestorWire, a specialized communications platform with a focus on advanced wire-grade press release syndication. InvestorWire is one of 75+ brands within the Dynamic Brand Portfolio @ IBN, which delivers access to a vast network of wire solutions, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution via IBN to millions of followers, and a full array of tailored corporate communications solutions. As Regentis continues to advance its clinical and commercial strategies, the strong interest from surgeons at the ICRS Summit signals potential for GelrinC to become a key player in the cartilage repair market, benefiting patients and investors alike. For more details, visit InvestorWire and see the full terms of use and disclaimers at https://www.InvestorWire.com/Disclaimer.
